Myonexus Therapeutics

Columbus
Ohio
United States

Tel: 614-477-5445

Email: triplett@myonexustx.com

Show jobs for this employer

About Myonexus Therapeutics

Myonexus Therapeutics is a clinical stage gene therapy company developing first ever treatments for Limb-girdle muscular dystrophy (LGMD) types 2D, 2B, 2E, 2L, and 2C based on research at Nationwide Children’s Hospital, a leader in muscular dystrophy gene therapy discovery and translational research.

YEAR FOUNDED:
February 2017

LEADERSHIP:
President and CEO: Michael Triplett, PhD
Treasurer & COO: Bruce Halpryn, PhD

8 articles with Myonexus Therapeutics